Genital Herpes: New Therapeutic Approaches Advance
New vaccines and a compound with new mechanism of action that are in early clinical trials suggest the poorly served antiherpes market could be rejuvenated in the next few years.
You may also be interested in...
Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.
Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.